Last updated: February 24, 2026
What Is NDC 00093-7295?
NDC 00093-7295 refers to a specific pharmaceutical product listed in the National Drug Code directory. Based on available data, this code corresponds to Eliquis (apixaban), an anticoagulant prescribed for stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Eliquis is marketed by Bristol-Myers Squibb and Pfizer.
Current Market Landscape
Competitive Positioning
Eliquis holds a leading position among oral anticoagulants. Its major competitors include:
- Xarelto (rivaroxaban) by Johnson & Johnson (Janssen)
- Pradaxa (dabigatran) by Boehringer Ingelheim
- Coumadin/warfarin, a traditional anticoagulant.
Eliquis commands approximately 30-35% of the oral anticoagulant market in the US as of 2022[1]. The drug's efficacy and safety profile, supported by large clinical trials (ARISTOTLE), contribute to its market dominance.
Market Size and Growth
The global anticoagulant market was valued at about USD 8.5 billion in 2022, projected to grow at a CAGR of 7.2% until 2030[2]. The US accounts for roughly 45% of this market, benefitting from an aging population and increased awareness of atrial fibrillation management.
In the US, anticoagulant prescriptions increased by 12% from 2017 to 2022, driven by updated treatment guidelines and expanding indications[3].
Regulatory and Policy Trends
- CMS and private insurer policies favor newer anticoagulants due to improved safety profiles.
- Patent exclusivity for Eliquis expires in 2026 in major markets, opening potential for generic competition.
Price Trajectory and Projections
Historical Pricing Trends
- In 2017, the average wholesale acquisition cost (WAC) for Eliquis was approximately USD 400 per month per patient.
- By 2022, WAC increased to approximately USD 450 per month, reflecting inflation and market dynamics.
Current Pricing Status
- Retail list prices vary, typically USD 10-15 per 2.5 mg tablet.
- Discounted average selling prices (ASP) for insurers tend to be around USD 8-12 per tablet.
- Average annual per-patient drug expenditure on Eliquis is approximately USD 5,400 to USD 6,000, depending on dosage and adherence.
Future Price Projections
Factors influencing potential price changes include:
- Generic Entry: Post-2026, generic versions are expected to significantly reduce Eliquis prices, with estimates suggesting a 50-70% price decline within the first year[4].
- Market Competition: Price competition among anticoagulants may prompt further discounts.
- Policy Environment: Payer negotiations and formulary decisions could lead to price restrictions.
- Inflation and Manufacturing Costs: Continue to exert upward pressure on list prices before patent expiration.
Given these factors, the following projections are reasonable:
| Year |
Estimated Average Wholesale Price (USD/month) |
Assumptions |
| 2023 |
USD 450-460 |
Slight increases due to inflation and demand |
| 2024 |
USD 455-470 |
Continued market stabilization |
| 2025 |
USD 460-480 |
Approaching patent expiration, early generic competition begins |
| 2026+ |
USD 200-250 (post-generic entry) |
Broad generic availability, steep decline expected |
Impact of Patent Expiration on Pricing
- Post-2026, prices may decline by up to 60-70%, aligning with generics' pricing historically seen with similar drugs.
- Market share shifts toward generics could reduce Eliquis's revenue by half or more.
Strategic Implications
- Investors should monitor patent expiry timelines and generic market entry to forecast revenues.
- Manufacturers may seek to extend patent protection or introduce biosimilars to sustain pricing.
- Healthcare providers and payers may negotiate discounts or favor alternative therapies to manage costs.
Key Takeaways
- Eliquis (NDC 00093-7295) is a leading anticoagulant with a sizable and growing market share.
- Its current pricing remains stable, but impending patent expiry in 2026 predicts significant price reductions.
- The US market drives growth within a global anticoagulant market projected to reach USD 16 billion by 2030.
- Market dynamics suggest a potential drop in average prices by 50-70% after generic competition materializes.
- Continuous monitoring of patent statuses and competitive launches is essential for accurate projections.
FAQs
How does Eliquis compare to other anticoagulants in pricing?
Eliquis generally costs more than warfarin but offers a better safety profile, resulting in higher adherence and reduced monitoring costs. Its current WAC is around USD 450/month, whereas warfarin is significantly cheaper but requires extensive monitoring.
When will generic versions of Eliquis become available?
Patent expiry is scheduled for 2026 in major markets, with generic versions anticipated shortly thereafter. The timeline may vary based on patent challenges and regulatory approvals.
What factors could accelerate or delay Eliquis's price decline?
Patent disputes, regulatory barriers, company strategies, or patent extensions could delay generic entry. Conversely, rapid approval and market acceptance of generics could accelerate price declines.
How will market competition influence Eliquis's future revenues?
Intensified competition from generics and other branded anticoagulants will likely lead to significant revenue declines post-2026. Market share may shift toward lower-priced alternatives.
What are the key risks for Eliquis's pricing and market position?
Patent expiration, generic market entry, regulatory changes, and payer reimbursement policies.
References
[1] IQVIA. (2022). Pharmaceutical Market Overview.
[2] Research and Markets. (2023). Global Anticoagulant Market Forecast 2023-2030.
[3] Centers for Disease Control and Prevention. (2022). Atrial Fibrillation and Anticoagulant Use.
[4] EvaluatePharma. (2022). Post-Patent Drug Pricing Trends.
